Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.

被引：0
|
作者：
Zhang, Xing
Wen, Xizhi
Chen, Guojuan
Zeng, Shan
Men, Lichuang
Wang, Hengbang
He, Shulan
Ma, Yuxiang
Pan, QiuZhong
Zhang, Yang
Peng, Ruiqing
Weng, Desheng
Liu, Wenqin
Zhang, Li
Liang, Zhiyan
Yang, Dajun
Zhai, Yifan
机构：
[1] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, Canc Ctr, Guangzhou, Peoples R China
[2] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[4] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11542
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers
    Pearson, A. T.
    Muzaffar, J.
    Bellile, E.
    Worden, F. P.
    Chung, C. H.
    Rosenberg, A.
    Vokes, E.
    Fidler, M. J.
    Brenner, J. C.
    Zhai, Y.
    Fu, T.
    Winkler, R.
    Swiecicki, P.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S79 - S80
  • [22] Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma
    Yamamoto, N.
    Lauer, U. M.
    Humphries, T.
    Natarajan, N.
    LoRusso, P.
    Prenen, H.
    Bartolome, J.
    He, M.
    Jayadeva, G.
    Teufel, M.
    Maerten, A.
    Kratz, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S342 - S343
  • [23] Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2-p53 antagonist
    Peltzer, Alexander
    Hesse, Raphael
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Patel, Manish R.
    Laurie, Scott
    Bauer, Todd Michael
    Teufel, Michael
    Geng, Junxian
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.
    Xu, B.
    Shen, L.
    Ye, D.
    Jappe, A.
    Wang, H.
    Yuan, R.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.
    Kurzrock, Razelle
    Blay, Jean-Yves
    Binh Bui Nguyen
    Wagner, Andrew J.
    Maki, Robert G.
    Schwartz, Gary K.
    Patnaik, Amita
    Gore, Lia
    Wu, Lin
    Vassilev, Lyubomir T.
    Ding, Michelle
    Geho, David
    Zhi, Jianguo
    Middleton, Steven
    Nichols, Gwen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Tang, Yuefen
    Wang, Hengbang
    Ji, Jiao
    Chen, Jason
    Liang, Zhiyan
    Amaya, Alex
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models of FLT3 mutant and TP53 wild-type acute myeloid leukemia
    Fang, Douglas D.
    Tang, Qiuqiong
    Wang, Qixin
    Li, Na
    Fang, Xu
    Gu, Jiaxing
    Kong, Yanhui
    Rong, Tao
    Wang, Guangfeng
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2020, 80 (16)
  • [28] Synergistic antitumor activity of lisaftoclax (APG-2575) and alrizomadlin (APG-115) through dual targeting of BCL-2/MDM2-P53 apoptotic pathways in preclinical models of acute myeloid leukemia
    Fang, Douglas D.
    Tang, Qiuqiong
    Wang, Qixin
    Li, Na
    Zhou, Feng
    Zhai, Guoqin
    Yin, Yan
    Yang, Dajun
    Zhai, Yifan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [29] A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Schoeffski, P.
    Yamamoto, N.
    Bauer, T.
    Patel, M.
    Gounder, M. M.
    Geng, J.
    Sailer, R.
    Jayadeva, G.
    Lorusso, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S743 - S743
  • [30] A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
    Gounder, Mrinal M.
    Bauer, Todd M.
    Schwartz, Gary K.
    Weise, Amy M.
    LoRusso, Patricia
    Kumar, Prasanna
    Tao, Ben
    Hong, Ying
    Patel, Parul
    Lu, Yasong
    Lesegretain, Arnaud
    Tirunagaru, Vijaya G.
    Xu, Feng
    Doebele, Robert C.
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1714 - +
12345